A Phase 2 interventional study of MYK-224 in Cardiomyopathy, Hypertrophic, sponsored by Bristol-Myers Squibb. Terminated at 25 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-02.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb — 9 open to participants now, 14 under way, 1 of them phase 3. Cardiomyopathy, Hypertrophic · Bristol-Myers Squibb.
Among the 31 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, this one is the 14th largest by enrollment of the 16 interventional ones that give a count, is one of 7 that started in 2023, is one of 4 in phase 2, and was the 13th registered.
363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.
Browse Cardiomyopathy, Hypertrophic studies →9 of the 31 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Japan
Ages 18+
Bristol-Myers Squibb · Sites in China
Ages 18+
Bristol-Myers Squibb · Sites in United Kingdom
Ages 18+
Bristol-Myers Squibb · Sites in Japan
Ages 18+
Bristol-Myers Squibb · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 6 · Phase 4 2
First in 2014; this study’s year is marked. 7 started in 2023.
This study's enrollment of 18 is below the median of 60 across 180 interventional studies indexed under Cardiomyopathy, Hypertrophic.
Median enrollment 55 across the 16 interventional studies, 200 across the 15 observational. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
6 of the studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06146660Bristol-Myers SquibbA Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy | 2026-11-30 |
| NCT07557498Bristol-Myers SquibbMavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US | 2026-12-14 |
| NCT07541833Bristol-Myers SquibbEffectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM) | 2026-12-31 |
| NCT06551129Bristol-Myers SquibbReal-world Patient Reported Outcomes Among Patients Treated With Camzyos | 2026-12-31 |
| NCT07846059Bristol-Myers SquibbEvaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic Cardiomyopathy | 2027-03-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 31 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to characterize the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of MYK-224 in participants with obstructive Hypertrophic Cardiomyopathy (oHCM)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Men or women diagnosed with oHCM consistent with current American College of Cardiology Foundation/American Heart Association and European Society of Cardiology guidelines, satisfying both of the following criteria:
AND
-- Has a LVOT peak gradient during screening as assessed by echocardiography of ≥ 50 millimeters of mercury (mm Hg) at rest, or ≥ 30 mm Hg at rest and ≥ 50 mm Hg with Valsalva maneuver (confirmed by echocardiography core laboratory interpretation).
Exclusion Criteria:
Other protocol-defined criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive MYK-224 either as a monotherapy or in combination with standard-of-care consisting of a beta-blocker. Participants who complete Cohort 1 will be eligible for an optional open label extension period
Drug: MYK-224
Participants will receive MYK-224 in combination with standard-of-care consisting of either a calcium channel blocker or disopyramide (which is given in combination with either a beta-blocker or calcium channel blocker). Participants who complete Cohort 2 will be eligible for an optional open label extension period
Drug: MYK-224
Specified dose on specified days
Also known as: BMS-986435
Part A: Number of Participants With Adverse Events and Serious Adverse Events
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization.
Time frame: From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)
Part A: Number of Participants With at Least One Event of Arrhythmias
Arrhythmias included atrial fibrillation/flutter (new from screening and recurrent), ventricular tachyarrhythmias (ventricular tachycardia, ventricular fibrillation, and Torsades de Pointe).
Time frame: From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)
Part A: Number of Participants With at Least One Event of Appropriate Implantable Cardioverter Defibrillator Therapy and Resuscitated Cardiac Arrest
Time frame: From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)
Part A: Change From Baseline in Vital Signs - Heart Rate
Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224. Heart rate was measured in rested state.
Time frame: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
Part A: Change From Baseline in Vital Signs - Mean Systolic Blood Pressure
Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224. Systolic blood pressure was measured in rested state.
Time frame: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
Part A: Change From Baseline in Vital Signs - Mean Diastolic Blood Pressure
Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224. Diastolic blood pressure was measured in rested state.
Time frame: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
Part A: Change From Baseline in Vital Signs - Respiratory Rate
Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224. Respiratory rate was measured in rested state.
Time frame: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
Part A: Change From Baseline in Vital Signs - Temperature
Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224.
Time frame: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
Part A: Change From Baseline in Vital Signs - Weight
Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224.
Time frame: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
Part A: Number of Participants With Abnormal Physical Examination Results
The complete physical examination included weight and calculated BMI, a neurological examination (gross motor and deep tendon reflexes),and an assessment of the following: general appearance, skin, head and neck, mouth, lymph nodes, thyroid, abdomen, musculoskeletal, cardiovascular, neurological, and respiratory systems with other systems included, as directed by interval history.
Time frame: Baseline and until study end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Results
Twelve-lead ECG evaluations will be performed in the supine position after 10 minutes of rest at Screening and at selected clinic visits prior to MYK-224 dosing and before any blood sample collection. QTc prolongation is defined by either the mean of QTcF \> 499 or mean of QTcB \> 499 according to the project requirement specification from Clario.
Time frame: Baseline and until study end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
Part A: Number of Participants With Adverse Events Related to Clinical Laboratory Parameters (Hematology, Chemistry and Urinalysis)
Blood samples were collected to assess the clinical laboratory parameters.
Time frame: Baseline and untill end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
Part A:Percentage of Participants With Incidence of Symptomatic Left Ventricular Ejection Fraction (LVEF) < 50%
LVEF was assessed using transthoracic echocardiogram (TTE) in resting state. 90% CIs are calculated based on Exact Binomial proportion test. LVEF value was calculated by Simpson Biplane method.
Time frame: From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)
Part A: Percentage of Participants With Incidence of Symptomatic Left Ventricular Ejection Fraction (LVEF) <= 30%
LVEF was assessed using transthoracic echocardiogram (TTE) in resting state. 90% CIs are calculated based on Exact Binomial proportion test. LVEF value was calculated by Simpson Biplane method.
Time frame: From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)
Part A: Aggregate Mean of Left Ventricular Ejection Fraction (LVEF)
Time frame: Treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
Part A: Change From Baseline in Left Ventricular Ejection Fraction (LVEF)
Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224. Participants with data available at the timepoint were included in the analysis.
Time frame: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
Part A: Aggregate Mean of Left Ventricular Outflow Tract (LVOT) Peak Gradient (Post-Exercise, Resting, and Valsalva)
Time frame: Treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
Part A: Change From Baseline in Left Ventricular Outflow Tract (LVOT) Peak Gradient (Post-Exercise, Resting, and Valsalva)
Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224. Participants with data available at the timepoint were included in the analysis.
Time frame: Treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
Part A: Percentage of Participants With Resting Left Ventricular Outflow Tract (LVOT) Peak Gradient < 30 mmHg and Valsalva LVOT Peak Gradient < 50 mmHg
Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224. 90%CIs are calculated based on Normal approximation.
Time frame: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
Part A: Plasma Concentration of MYK-224
Blood samples were collected to assess plasma concentration of MYK-224.
Time frame: Pre-dose and 1 hour post-dose end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
| Milestone | Part A - Dose Treatment - MYK-224 | Part B - Open Label Extension - MYK-224 |
|---|---|---|
| Started | 18 | 0 |
| Completed | 17 | 0 |
| Not completed | 1 | 0 |
| Withdrew: Other reasons | 1 | 0 |
| Milestone | Part A - Dose Treatment - MYK-224 | Part B - Open Label Extension - MYK-224 |
|---|---|---|
| Started | 0 | 16 |
| Completed | 0 | 0 |
| Not completed | 0 | 16 |
| Withdrew: Study terminated by sponsor | 0 | 16 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization.
| Participants | Part A - Dose Treatment - MYK-224 |
|---|---|
| Participants with at least one adverse events in Part A | 15 |
| Participants with at least one serious adverse events in Part A | 0 |
Arrhythmias included atrial fibrillation/flutter (new from screening and recurrent), ventricular tachyarrhythmias (ventricular tachycardia, ventricular fibrillation, and Torsades de Pointe).
| Participants | Part A - Dose Treatment - MYK-224 |
|---|---|
| Atrial Fibrillation/Flutter | 2 |
| Ventricular Tachyarrhythmias | 1 |
| Participants | Part A - Dose Treatment - MYK-224 |
|---|---|
| Part A: Number of Participants With at Least One Event of Appropriate Implantable Cardioverter Defibrillator Therapy and Resuscitated Cardiac Arrest | 1 |
Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224. Heart rate was measured in rested state.
| beats per minute | Part A - Dose Treatment - MYK-224 |
|---|---|
| Part A: Change From Baseline in Vital Signs - Heart Rate | 0.9 ± 8.96 |
Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224. Systolic blood pressure was measured in rested state.
| mmHg | Part A - Dose Treatment - MYK-224 |
|---|---|
| Part A: Change From Baseline in Vital Signs - Mean Systolic Blood Pressure | 2.5 ± 18.25 |
Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224. Diastolic blood pressure was measured in rested state.
| mmHg | Part A - Dose Treatment - MYK-224 |
|---|---|
| Part A: Change From Baseline in Vital Signs - Mean Diastolic Blood Pressure | 4.2 ± 12.62 |
Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224. Respiratory rate was measured in rested state.
| breaths per minute | Part A - Dose Treatment - MYK-224 |
|---|---|
| Part A: Change From Baseline in Vital Signs - Respiratory Rate | 0.6 ± 2.23 |
Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224.
| Celsius | Part A - Dose Treatment - MYK-224 |
|---|---|
| Part A: Change From Baseline in Vital Signs - Temperature | -0.09 ± 0.280 |
Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224.
| kilogram | Part A - Dose Treatment - MYK-224 |
|---|---|
| Part A: Change From Baseline in Vital Signs - Weight | 0.89 ± 3.168 |
The complete physical examination included weight and calculated BMI, a neurological examination (gross motor and deep tendon reflexes),and an assessment of the following: general appearance, skin, head and neck, mouth, lymph nodes, thyroid, abdomen, musculoskeletal, cardiovascular, neurological, and respiratory systems with other systems included, as directed by interval history.
| Participants | Part A - Dose Treatment - MYK-224 |
|---|---|
| Cardiovascular | 11 |
| Skin | 1 |
| Other | 1 |
Twelve-lead ECG evaluations will be performed in the supine position after 10 minutes of rest at Screening and at selected clinic visits prior to MYK-224 dosing and before any blood sample collection. QTc prolongation is defined by either the mean of QTcF \> 499 or mean of QTcB \> 499 according to the project requirement specification from Clario.
| Participants | Part A - Dose Treatment - MYK-224 |
|---|---|
| QTC PROLONGATION (Baseline) | 3 |
| QTC PROLONGATION (end date) | 2 |
| ST DEPRESSION (Baseline) | 4 |
| ST DEPRESSION (end date) | 2 |
| T WAVES FLAT (Baseline) | 1 |
| T WAVES FLAT (end date | 1 |
| T WAVE INVERSION (Baseline) | 7 |
| T WAVE INVERSION (end date) | 3 |
| ATRIAL FIBRILLATION/FLUTTER (Baseline) | 5 |
| ATRIAL FIBRILLATION/FLUTTER (End date) | 1 |
Blood samples were collected to assess the clinical laboratory parameters.
| Participants | Part A - Dose Treatment - MYK-224 |
|---|---|
| Chemistry (Elevated Alanine Aminotransferase) | 1 |
| Chemistry (Transaminases increased) | 1 |
| Hematology | 0 |
| Urinalysis | 0 |
LVEF was assessed using transthoracic echocardiogram (TTE) in resting state. 90% CIs are calculated based on Exact Binomial proportion test. LVEF value was calculated by Simpson Biplane method.
| percentage of participants | Part A - Dose Treatment - MYK-224 |
|---|---|
| Part A:Percentage of Participants With Incidence of Symptomatic Left Ventricular Ejection Fraction (LVEF) < 50% | 0 (0 to 0) |
LVEF was assessed using transthoracic echocardiogram (TTE) in resting state. 90% CIs are calculated based on Exact Binomial proportion test. LVEF value was calculated by Simpson Biplane method.
| percentage of participants | Part A - Dose Treatment - MYK-224 |
|---|---|
| Part A: Percentage of Participants With Incidence of Symptomatic Left Ventricular Ejection Fraction (LVEF) <= 30% | 0 (0 to 0) |
| percentage | Part A - Dose Treatment - MYK-224 |
|---|---|
| Part A: Aggregate Mean of Left Ventricular Ejection Fraction (LVEF) | 65.0 ± 4.09 |
Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224. Participants with data available at the timepoint were included in the analysis.
| percentage | Part A - Dose Treatment - MYK-224 |
|---|---|
| Part A: Change From Baseline in Left Ventricular Ejection Fraction (LVEF) | 0.1 ± 4.31 |
| mmHg | Part A - Dose Treatment - MYK-224 |
|---|---|
| Resting LVOT | 25.423 ± 23.5685 |
| Valsalva LVOT | 43.888 ± 36.1765 |
| Post-Exercise LVOT | 56.965 ± 45.1914 |
Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224. Participants with data available at the timepoint were included in the analysis.
| mmHg | Part A - Dose Treatment - MYK-224 |
|---|---|
| Resting LVOT | -49.093 ± 30.9153 |
| Valsalva LVOT | -51.079 ± 36.1091 |
| Post-Exercise LVOT | -34.654 ± 43.1174 |
Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224. 90%CIs are calculated based on Normal approximation.
| percentage of participants | Part A - Dose Treatment - MYK-224 |
|---|---|
| Part A: Percentage of Participants With Resting Left Ventricular Outflow Tract (LVOT) Peak Gradient < 30 mmHg and Valsalva LVOT Peak Gradient < 50 mmHg | 61.1 (42.21 to 80.01) |
Blood samples were collected to assess plasma concentration of MYK-224.
| ng/mL | Part A - Dose Treatment - MYK-224 |
|---|---|
| MYK-224 Monotherapy - Pre-Dose | 189.113 ± 65.6285 |
| MYK-224 Monotherapy, 1 hour Post-dose | 280.621 ± 49.9295 |
| MYK-224 + Beta Blockers - Pre-Dose | 136.926 ± 111.1556 |
| MYK-224 + Beta Blockers - 1 hour Post-dose | 199.685 ± 92.7083 |
Collected over All cause mortality and adverse events were collected from from first dose (Day 1) until study end date in Part A or B or 30 days after early termination date (Median 69.05 weeks and Maximum 85.0 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A - Dose Treatment - MYK-224 | 0/18 (0%) | 0/18 (0%) | 15/18 (83.3%) |
| Part B - Open Label Extension - MYK-224 | 0/16 (0%) | 3/16 (18.8%) | 6/16 (37.5%) |
| Event | Part A - Dose Treatment - MYK-224 | Part B - Open Label Extension - MYK-224 |
|---|---|---|
| EpilepsyNervous system disorders | 0/18 | 1/16 |
| PresyncopeNervous system disorders | 0/18 | 1/16 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/18 | 1/16 |
| Event | Part A - Dose Treatment - MYK-224 | Part B - Open Label Extension - MYK-224 |
|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 7/18 | 0/16 |
| HeadacheNervous system disorders | 5/18 | 0/16 |
| FatigueGeneral disorders | 4/18 | 1/16 |
| InfluenzaInfections and infestations | 4/18 | 0/16 |
| DizzinessNervous system disorders | 4/18 | 0/16 |
| Atrial fibrillationCardiac disorders | 2/18 | 1/16 |
| Chest discomfortGeneral disorders | 2/18 | 0/16 |
| HypertensionVascular disorders | 2/18 | 1/16 |
| Angina pectorisCardiac disorders | 1/18 | 1/16 |
| Oedema peripheralGeneral disorders | 1/18 | 1/16 |
| Age, Continuous(years) | Part A - Dose Treatment - MYK-224 |
|---|---|
| Mean | 59.8 ± 9.08 |
| Sex: Female, Male(Participants) | Part A - Dose Treatment - MYK-224 |
|---|---|
| Female | 5 |
| Male | 13 |
| Ethnicity (NIH/OMB)(Participants) | Part A - Dose Treatment - MYK-224 |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 14 |
| Unknown or Not Reported | 2 |
| Race (NIH/OMB)(Participants) | Part A - Dose Treatment - MYK-224 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 17 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| BACKGROUND HCM THERAPY(Participants) | Part A - Dose Treatment - MYK-224 |
|---|---|
| BETA BLOCKER USE AT BASELINE | 9 |
| CALCIUM CHANNEL BLOCKER USE AT BASELINE | 0 |
| DISOPYRAMIDE USE AT BASELINE | 0 |
| NONE | 9 |
| Implantable Cardioverter Defibrillator (ICD) Therapy Use(Participants) | Part A - Dose Treatment - MYK-224 |
|---|---|
| Yes | 5 |
| No ICD use | 13 |
| NYHA FUNCTIONAL CLASS(Participants) | Part A - Dose Treatment - MYK-224 |
|---|---|
| CLASS I | 1 |
| CLASS II | 12 |
| CLASS III | 5 |
| CLASS IV | 0 |
| LEFT VENTRICULAR EJECTION FRACTION(percentage) | Part A - Dose Treatment - MYK-224 |
|---|---|
| Mean | 65.4 ± 4.23 |
6 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Ran from Jan 2023 to primary completion in Aug 2024, 19 months.
Results were first posted in Jun 2026, 1 year 9 months after primary completion. A results delay was requested in Aug 2025.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Delocamten
Cardiomyopathy, Hypertrophic →